Clinical trials: Chronic Health Conditions
- Condition Chronic Health Conditions
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Chronic Myeloid Leukaemia
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary.
- Trial name
- NCT05286528
- Testing
- Bosutinib, Imatinib, Nilotinib
- Where
- Hungary
- Volunteers
- 1,484 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
QVA Mechanistic Efficacy Study (Receptor Effects, Etc)
The purpose of this study was to assess global ventilated lung volume in moderate to severe COPD patients using MRI lung imaging after treatment with QVA149 compared to placebo.
- Trial name
- NCT02634983
- Testing
- QVA149
- Where
- 3 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
This is a pilot study to investigate the effect of danirixin hydrobromide 35 milligram (mg) tablets on lung function and health related quality of life (HRQoL) in subjects with mild to moderate airflow obstruction and a…
- Trial name
- NCT03170232
- Testing
- Danirixin 35 mg tablets, Metered dose inhaler (MDI) sensor device, Rescue medication
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)
The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto® Respimat® according to label after approximately 6 weeks in routine…
- Trial name
- NCT03165045
- Testing
- Spiolto® Respimat®
- Where
- 108 sites in Germany
- Volunteers
- 1,351 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at data from people with chronic obstructive pulmonary disease (COPD). Some used Stiolto Respimat and the others Trelegy Ellipta as their first treatment for COPD.
- Trial name
- NCT05169424
- Testing
- Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg)
- Where
- United States
- Volunteers
- 9,117 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium/Formoterol Fixed Combination Dose Finding Study
The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials
- Trial name
- NCT00626522
- Testing
- Aclidinium bromide and formoterol
- Where
- 9 sites in Australia, Czechia and 2 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness
The main purpose of the study is to assess the burden of illness for, COPD using both patient-reported symptom burden and claims-based economic burden, among the subjects treated with single-inhaler dual therapy treatments…
- Trial name
- NCT03543176
- Testing
- UMEC/VI, FLUT/SAL, CAT
- Where
- United States
- Volunteers
- 789 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Home-Based Health Management of COPD Patients
Minnesota HealthSolutions Corporation (MHS) proposes to develop and evaluate a program to motivate and monitor people with chronic obstructive pulmonary disease (COPD) to complete home exercise as part of pulmonary rehabilitation…
- Trial name
- NCT02557178
- Testing
- health coaching
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Sara Seifert
Pulmonary Disease, Chronic Obstructive
Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV
This is a 12 month randomized, open-label, parallel-group study to obtain data on the frequency and variability of exacerbations in severe and very severe Chronic Obstructive Pulmonary Disease (COPD) patients (Global Initiative…
- Trial name
- NCT00527826
- Testing
- Salmeterol / Fluticasone (50/500 µg) BID fixed combination, Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers
- Where
- 23 sites in Germany
- Volunteers
- 214 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)
This study evaluated the effect of QAB149 on dynamic and static hyperinflation, breathlessness, and health status in COPD patients
- Trial name
- NCT00636961
- Testing
- Indacaterol 300μg
- Where
- 3 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Novartis
COPD
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
The main goal of this study is to evaluate the efficacy and safety of glycopyrronium bromide and indacaterol maleate and glycopyrronium bromide fixed dose combination (FDC) in patients with moderate COPD who switch from their…
- Trial name
- NCT01985334
- Testing
- Glycopyrronium, SABA, LABA
- Where
- 542 sites in Austria, Belgium and 21 more
- Volunteers
- 4,389 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, Health Knowledge, Attitudes, Practice
Improving Diabetic Patient Health Through Assistive-Reading Technology
Type 2 Diabetes Mellitus (T2DM) affects over 30 million Americans and requires patients to competently manage their conditions at home.
- Conditions
- Diabetes Mellitus, Type 2, Health Knowledge, Attitudes, Practice, Literacy
- Trial name
- NCT05337306
- Testing
- GogyUp Reader
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- GogyUp Inc
Pulmonary Disease, Chronic Obstructive
Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug
The objective of this non-interventional, observational study is to assess whether changing Chronic Obstructive Pulmonary Disease (COPD) patients from a dry powder inhaler (HandiHaler®) to a soft mist inhaler (Respimat®), without…
- Trial name
- NIS PIRATE (NCT05362487)
- Testing
- Spiriva® Respimat®, Spiriva® HandiHaler®, Tiotropium bromide
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test
To evaluate the early (3-month) impact of the long-acting anticholinergic Spiriva HH maintenance treatment on the COPD symptoms using the novel COPD Assessment test (CAT) in the real life setting of COPD patients, previously…
- Trial name
- NCT01644734
- Testing
- Spiriva HandiHaler
- Where
- 247 sites in Poland
- Volunteers
- 1,328 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C Chronic
Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)
This is an observational prospective follow-up study to assess the utilization of boceprevir and the management of pre-specified health outcomes of interest (HOIs) under conditions of routine clinical care in participants with…
- Trial name
- NCT01544582
- Volunteers
- 713 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure, Reduced Ejection Fraction
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection…
- Trial name
- AWAKE-HF (NCT02970669)
- Testing
- sacubitril/valsartan (LCZ696), enalapril
- Where
- 23 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the efficacy and safety of QVA149 compared to tiotropium plus formoterol in patients with moderate to severe COPD.
- Trial name
- QUANTIFY (NCT01574651)
- Testing
- QVA149, Tiotropium, Formoterol
- Where
- 144 sites in Germany
- Volunteers
- 934 people
- Sponsor
- Novartis Pharmaceuticals
End Stage Renal Disease
Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial)
To conduct a pragmatic randomized clinical trial in which the researchers will determine the mortality impact of a protocol whereby all hemodialysis patients receive an oral, protein-based nutritional supplement during the…
- Trial name
- HELPS-HD (NCT02933151)
- Testing
- Nutritional Supplement
- Where
- 2 sites in United States
- Volunteers
- 10,457 people
- Sponsor
- Dialysis Clinic, Inc.
Chronic Pain
Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System
This is a proof of concept study to measure the effect of Wearable Health Technology (WHT), including the Apple Watch, iPhone, Pain App and Provider Dashboards on important clinical outcomes in patients treated for chronic pain.
- Trial name
- NCT03299556
- Testing
- WHT
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Purdue Pharma LP
Periodontal Diseases, Chronic Periodontitis
Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome
The purpose of this study was to demonstrate in patients with generalized chronic periodontitis that switching from cigarette smoking to using IQOS improves the response to periodontal therapy and the overall oral health status…
- Conditions
- Periodontal Diseases, Chronic Periodontitis, Periodontal Pocket, Tooth Mobility
- Trial name
- NCT03364751
- Testing
- IQOS, Cigarette
- Where
- 26 sites in Japan
- Volunteers
- 179 people
- Sponsor
- Philip Morris Products S.A.